Yogen Saunthararajah

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. ncbi CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors
    S Negrotto
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Leukemia 26:244-54. 2012
  2. ncbi p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies
    Yogen Saunthararajah
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Semin Oncol 39:97-108. 2012
  3. ncbi S110, a novel decitabine dinucleotide, increases fetal hemoglobin levels in baboons (P. anubis)
    Donald Lavelle
    Department of Medicine, University of Illinois at Chicago, 840 S, Wood St, Chicago, Illinois 60612 7323, USA
    J Transl Med 8:92. 2010
  4. ncbi Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo
    Oscar Alcazar
    Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA
    Int J Cancer 131:18-29. 2012
  5. ncbi Noncytotoxic differentiation treatment of renal cell cancer
    Soledad Negrotto
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA
    Cancer Res 71:1431-41. 2011
  6. ncbi Expression of phosphorylated signal transducer and activator of transcription 5 is associated with an increased risk of death in acute myeloid leukemia
    Anna Brady
    Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Eur J Haematol 89:288-93. 2012
  7. ncbi Race and intensity of post-remission therapy in acute myeloid leukemia
    Anna K Brady
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
    Leuk Res 35:346-50. 2011
  8. ncbi Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice
    Pierre L Triozzi
    Taussig Cancer Institute, R40, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Cancer Immunol Immunother 61:1441-50. 2012
  9. ncbi Monosomy 3 by FISH in uveal melanoma: variability in techniques and results
    Mary Aronow
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Surv Ophthalmol 57:463-73. 2012
  10. ncbi High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects
    Quteba Ebrahem
    Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
    Oncotarget 3:1137-45. 2012

Research Grants

  1. Optimizing decitabine regimen + formulation for nonDNA damaging DNMT1 depletion
    Yogen Saunthararajah; Fiscal Year: 2009
  2. Optimizing decitabine regimen + formulation for nonDNA damaging DNMT1 depletion
    Yogen Saunthararajah; Fiscal Year: 2010

Collaborators

  • Mikkael A Sekeres
  • Pierre Triozzi
  • Edward Copelan
  • Anjali Advani
  • Arun D Singh
  • Jaroslaw Maciejewski
  • Ramon V Tiu
  • Charis Eng
  • J C Mulloy
  • Anna Jankowska
  • Azra Raza
  • Steven Ackerman
  • Ying Jiang
  • Claudiu V Cotta
  • J Bodo
  • Harinder Singh
  • Daniel Lindner
  • Marc Earl
  • Zhenbo Hu
  • Quteba Ebrahem
  • Soledad Negrotto
  • Reda Z Mahfouz
  • Valeria Visconte
  • Oscar Alcazar
  • Matt Kalaycio
  • Xiaorong Gu
  • Kwok Peng Ng
  • S Negrotto
  • Mary Aronow
  • Anna Brady
  • Nelli Bejanyan
  • Ronald Sobecks
  • Raymond Tubbs
  • Anna K Brady
  • Virginia Torres
  • Donald Lavelle
  • Kenneth Chan
  • Pramod Terse
  • Joseph Covey
  • Kory J Engelke
  • Ali Tabarroki
  • Yonghua Ling
  • Tomas Radivoyevitch
  • Fabiola Traina
  • Josephine Chan
  • Kazunori Koide
  • Hadrian Szpurka
  • Susan Achberger
  • Eric Hsi
  • John Barnard
  • E Hsi
  • Yang Sun
  • Heesun J Rogers
  • B Gopalan
  • Hideki Makishima
  • Manoj Bupathi
  • K P Ng
  • Charles Biscotti
  • Jarnail Singh
  • Sami Osman
  • Kyoichi Isono
  • Andres Jerez
  • Wayne Aldrich
  • James McMahon
  • Christine O'Keefe
  • Jennifer Bates
  • K Guinta
  • Haruhiko Koseki
  • Lindsey Mooney
  • Sarah Gibson
  • Richard A Padgett
  • Lisa Rybicki
  • Alex Z Fu
  • Vinzon Ibanez
  • ShriHari Kadkol
  • Lynn Schoenfiled
  • Kristine Baraoidan
  • Arun Sharma
  • Giuseppina Nucifora
  • Brian Rini
  • Reinhold Munker
  • John W Crabb
  • Chongtie Shi
  • Pasit Phiasivongsva
  • Sanjeev Redkar
  • Virryan Banzon
  • Kestis Vaitkus
  • Roger Inloes
  • Sarath Kanekal
  • David Bearss

Detail Information

Publications19

  1. ncbi CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors
    S Negrotto
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Leukemia 26:244-54. 2012
    ....
  2. ncbi p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies
    Yogen Saunthararajah
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Semin Oncol 39:97-108. 2012
    ..Decitabine or 5-azacytidine dose and schedule can be rationalized to emphasize this mechanism of action, as an alternative or complement to conventional apoptosis-based oncotherapy...
  3. ncbi S110, a novel decitabine dinucleotide, increases fetal hemoglobin levels in baboons (P. anubis)
    Donald Lavelle
    Department of Medicine, University of Illinois at Chicago, 840 S, Wood St, Chicago, Illinois 60612 7323, USA
    J Transl Med 8:92. 2010
    ..In these experiments the effect of S110 on HbF levels in baboons and its ability to reduce DNA methylation of the γ-globin gene promoter in vivo were evaluated...
  4. ncbi Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo
    Oscar Alcazar
    Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA
    Int J Cancer 131:18-29. 2012
    ..Modification of decitabine dose, schedule and formulation for differentiation rather than cytotoxic objectives inhibits the growth of melanoma cells in vitro and in vivo...
  5. ncbi Noncytotoxic differentiation treatment of renal cell cancer
    Soledad Negrotto
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA
    Cancer Res 71:1431-41. 2011
    ..The distinctive mechanism of action of a dose and schedule of DAC designed for noncytotoxic depletion of DNMT1 suggests a potential role in treating RCC...
  6. ncbi Expression of phosphorylated signal transducer and activator of transcription 5 is associated with an increased risk of death in acute myeloid leukemia
    Anna Brady
    Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    Eur J Haematol 89:288-93. 2012
    ..Constitutive activation of STAT5 (by phosphorylation) has been identified in a number of malignancies, including acute myeloid leukemia (AML)...
  7. ncbi Race and intensity of post-remission therapy in acute myeloid leukemia
    Anna K Brady
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
    Leuk Res 35:346-50. 2011
    ..In many cancers, including AML, blacks have poorer overall survival. We investigated whether differences in post-remission therapy (PRT) were a contributing factor...
  8. ncbi Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice
    Pierre L Triozzi
    Taussig Cancer Institute, R40, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Cancer Immunol Immunother 61:1441-50. 2012
    ..Effects on host immune effector and suppressor responses have not been well characterized...
  9. ncbi Monosomy 3 by FISH in uveal melanoma: variability in techniques and results
    Mary Aronow
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Surv Ophthalmol 57:463-73. 2012
    ..FISH is a widely available, versatile technology, and when performed optimally has the potential to be a valuable tool for determining the prognosis of uveal melanoma...
  10. ncbi High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects
    Quteba Ebrahem
    Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA
    Oncotarget 3:1137-45. 2012
    ..This protection can be reversed without increasing myelotoxicity by combining tetrahydrouridine with a lower dose of decitabine...
  11. ncbi Decitabine maintains hematopoietic precursor self-renewal by preventing repression of stem cell genes by a differentiation-inducing stimulus
    Zhenbo Hu
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Mol Cancer Ther 9:1536-43. 2010
    ..Using decitabine to deplete DNMT1 after this early repression phase does not impair progressive differentiation...
  12. ncbi Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy
    Reda Z Mahfouz
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Clin Cancer Res 19:938-48. 2013
    ....
  13. ncbi A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF)
    Nelli Bejanyan
    Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA
    Cancer 118:3968-76. 2012
    ..In this phase 2 study, the authors combined multiple active agents (thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid [TADA]) to treat patients with these disorders...
  14. ncbi Chromosome 3 status in uveal melanoma: a comparison of fluorescence in situ hybridization and single-nucleotide polymorphism array
    Arun D Singh
    Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Invest Ophthalmol Vis Sci 53:3331-9. 2012
    ..To compare fluorescence in situ hybridization (FISH) using a centromeric probe for chromosome 3 (CEP3) and 3p26 locus-specific probe with single-nucleotide polymorphism array (SNP-A) analysis in the detection of high-risk uveal melanoma...
  15. ncbi Aberrant DNA methylation is a dominant mechanism in MDS progression to AML
    Ying Jiang
    Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland Clinic, OH 44195, USA
    Blood 113:1315-25. 2009
    ..However, the ubiquity, extent, and correlation with disease progression suggest that aberrant DNA methylation is the dominant mechanism for TSG silencing and clonal variation in MDS evolution to AML...
  16. ncbi RUNX1 regulates corepressor interactions of PU.1
    Zhenbo Hu
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Blood 117:6498-508. 2011
    ..1 and mutated or translocated RUNX1. RUNX1 deficiency is associated with persistent corepressor interaction with PU.1. Thus, inhibiting HDAC can partly compensate for the functional consequences of RUNX1 deficiency...
  17. ncbi SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes
    Valeria Visconte
    Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, OH, USA
    Blood 120:3173-86. 2012
    ..In conclusion, we report the first experimental evidence of the association between SF3B1 and RS phenotype. Our data suggest that SF3B1 haploinsufficiency leads to RS formation...
  18. ncbi Circulating tumor cells in uveal melanoma
    Virginia Torres
    Taussig Cancer Institute, Cleveland Clinic Foundation, Ohio, USA
    Future Oncol 7:101-9. 2011
    ..However, more research on the biology of uveal melanoma as well as improvements upon the current technologies are needed...
  19. ncbi A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia
    Anjali S Advani
    Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44195, USA
    Leuk Res 34:1622-6. 2010
    ..The maximum tolerated dose of IM was 300 mg. The dose-limiting toxicity was Grade 3-4 hepatic toxicity. The CR/CRp rate was 57%. Cytotoxic therapy that includes IM for relapsed AML is well-tolerated and effective...

Research Grants2

  1. Optimizing decitabine regimen + formulation for nonDNA damaging DNMT1 depletion
    Yogen Saunthararajah; Fiscal Year: 2009
    ....
  2. Optimizing decitabine regimen + formulation for nonDNA damaging DNMT1 depletion
    Yogen Saunthararajah; Fiscal Year: 2010
    ....